drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically modified to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA/TNFRSF17) on multiple myeloma cells, enabling antigen-specific T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds BCMA (TNFRSF17) on multiple myeloma cells, leading to antigen-specific T‑cell activation, proliferation, cytokine release, and cytotoxic killing of BCMA‑expressing tumor cells.
drug_name
BCMA CAR-T cells
nct_id_drug_ref
NCT05740891